JP2024513388A - 複合薬物粒子及びその使用 - Google Patents

複合薬物粒子及びその使用 Download PDF

Info

Publication number
JP2024513388A
JP2024513388A JP2023560463A JP2023560463A JP2024513388A JP 2024513388 A JP2024513388 A JP 2024513388A JP 2023560463 A JP2023560463 A JP 2023560463A JP 2023560463 A JP2023560463 A JP 2023560463A JP 2024513388 A JP2024513388 A JP 2024513388A
Authority
JP
Japan
Prior art keywords
acid
salt
composite particles
particles
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513388A5 (cg-RX-API-DMAC7.html
Inventor
アデフェソ オモローラ エニオラ
マイケル エル フェルダー
ハニエ サファリ
ダニエル クポー
Original Assignee
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン filed Critical ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン
Publication of JP2024513388A publication Critical patent/JP2024513388A/ja
Publication of JP2024513388A5 publication Critical patent/JP2024513388A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023560463A 2021-03-31 2022-03-31 複合薬物粒子及びその使用 Pending JP2024513388A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163168829P 2021-03-31 2021-03-31
US63/168,829 2021-03-31
PCT/US2022/022848 WO2022212717A1 (en) 2021-03-31 2022-03-31 Composite drug particles and uses thereof

Publications (2)

Publication Number Publication Date
JP2024513388A true JP2024513388A (ja) 2024-03-25
JP2024513388A5 JP2024513388A5 (cg-RX-API-DMAC7.html) 2025-04-08

Family

ID=83456771

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560463A Pending JP2024513388A (ja) 2021-03-31 2022-03-31 複合薬物粒子及びその使用

Country Status (4)

Country Link
US (1) US20240165130A1 (cg-RX-API-DMAC7.html)
EP (1) EP4312991A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024513388A (cg-RX-API-DMAC7.html)
WO (1) WO2022212717A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102979350B1 (ko) * 2023-03-07 2026-06-18 아주대학교산학협력단 글루코코르티코이드계 화합물을 포함하는 염증의 예방 또는 치료용 약학적 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185764A1 (en) * 2000-04-17 2003-10-02 Staniforth John Nicholas Pharmaceutical formulations for dry powder inhalers
JP2003530425A (ja) * 2000-04-17 2003-10-14 ヴェクトゥラ リミテッド 吸入器で使用するための製剤におけるまたはそれに関する改良
JP2007516259A (ja) * 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
US20130273172A1 (en) * 2010-10-21 2013-10-17 Cadila Healthcare Limited Topical pharmaceutical compositions containing nanodroplets for the treatment psoriasis
WO2021011753A1 (en) * 2019-07-16 2021-01-21 The Regents Of The University Of Michigan Composite drug particles and uses thereof
CN112915916A (zh) * 2021-01-29 2021-06-08 江南大学 一种pH刺激响应型胆汁盐Pickering复合乳化剂

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185764A1 (en) * 2000-04-17 2003-10-02 Staniforth John Nicholas Pharmaceutical formulations for dry powder inhalers
JP2003530425A (ja) * 2000-04-17 2003-10-14 ヴェクトゥラ リミテッド 吸入器で使用するための製剤におけるまたはそれに関する改良
JP2007516259A (ja) * 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
US20130273172A1 (en) * 2010-10-21 2013-10-17 Cadila Healthcare Limited Topical pharmaceutical compositions containing nanodroplets for the treatment psoriasis
WO2021011753A1 (en) * 2019-07-16 2021-01-21 The Regents Of The University Of Michigan Composite drug particles and uses thereof
CN112915916A (zh) * 2021-01-29 2021-06-08 江南大学 一种pH刺激响应型胆汁盐Pickering复合乳化剂

Also Published As

Publication number Publication date
EP4312991A1 (en) 2024-02-07
WO2022212717A1 (en) 2022-10-06
US20240165130A1 (en) 2024-05-23
EP4312991A4 (en) 2025-01-29

Similar Documents

Publication Publication Date Title
CN103764151B (zh) Cb1受体拮抗剂
Nohria et al. Ganaxolone
AU2009201951A1 (en) Pregnane steroids for use in the treatment of CNS disorders
Schürmeyer et al. Reversible azoospermia induced by the anabolic steroid 19-nortestosterone
JPH06505958A (ja) 脳興奮性調節のための方法、組成物および化合物
WO2013064620A1 (de) 18-METHYL-6,7-METHYLEN-3-OXO-17-PREGN-4-EN-21,17β-CARBOLACTONE, PHARMAZEUTISCHE PRÄPARATE ENTHALTEND DIE GENANNTEN VERBINDUNGEN UND DEREN ANWENDUNG BEI DER THERAPIE DER ENDOMETRIOSE
US20220257523A1 (en) Composite drug particles and uses thereof
Amer et al. Pharmaceutical and Pharmacological Evaluation of the Effect of Nano-Formulated Spironolactone and Progesterone on Inflammation and Hormonal Levels for Managing Hirsutism Experimentally Induced in Rats: Topical Lipid-Based Nano-Formulation in Hirsutism
JPH03500049A (ja) ストレス、不安および発作活性の緩和のための組成物および方法
US20240165130A1 (en) Composite drug particles and uses thereof
Yu et al. The endogenic neurosteroid system and its role in the pathogenesis and therapy of mental disorders
Zhu et al. Approved Steroidal Drugs (2000–2025): A Medicinal Chemistry Perspective
EP2925770B1 (en) 3-(4'-substituted)-benzyl-ether derivatives of pregnenolone
CA2585359C (en) Gaba-steroid antagonists and their use for the treatment of cns disorders
CN108779142A (zh) 选择性孕酮受体调节剂(SPRM) (11.β.,17.β.)-17-羟基-11-[4-(甲基磺酰基)苯基]-17-(五氟乙基)雌甾-4,9-二烯-3-酮的前药
JPH11507050A (ja) 前立腺病の処置および予防
Watanabe et al. Stimulation of gastric acid secretion by progesterone metabolites as neuroactive steroids in anesthetized rats
Sitruk-Ware Progesterone and Progestins in Women’s Health
WO2026020071A1 (en) Autogenous therapeutic lipid carriers
CN112955129A (zh) 包含类固醇类药物的生物降解性高分子微粒及其制备方法
RU2355406C2 (ru) Средство для стимуляции роста мотонейронов спинного мозга растущего организма млекопитающих и способ его применения
Sullivan et al. Androgen regulation of ocular mucosal-and auto-immunity
HK40056265A (en) Biodegradable polymer microparticle containing steroid-based drug and preparation method therefor
WO2007104576A1 (de) Arzneimittel enthaltend n-acetyl-mannosamin oder derivate hiervon und seine verwendung
Wang et al. Neurosteroid: Molecular Mechanisms of Action on the GABAA Receptor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260701